A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. METHODS: We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. RESULTS: ). Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides PNPLA3 p.I148M and TM6SF2 p.E167K, additional variants, including common risk variants in MBOAT7 , GCKR , GPAM , protective variants in HSD17B13 , APOE and MTARC1, and rare variants ( e.g. in APOB , MTTP, CIDEB and ATG7 ), have been robustly associated with the risk of progressive MASLD. 199 -205”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the periportal hepatocyte-enriched genes HSD17B13152 and PNPLA3153 are associated with NASH”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“To demonstrate this, we examined the trans associations with a splice variant in HSD17B13 (rs72613567), known to protect against chronic liver disease42.”
From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [42]
In the citing paper
“These findings inform the prioritization of therapeutic targets, providing clues to potential on-target side effects and opportunities for drug repurposing87–89.”
From A brief history of human disease genetics (2020) · cites this paper as [88]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Cited by
Items 701–800 of 831
Mitochondrial dysfunction and lipid droplet dynamics in MASH: HSD17B13 as a therapeutic target
Noor, S., Tian, Y., & Su, W. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1912237 · Cited by 1
Current therapeutic landscape and future treatment perspectives of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10672-8 · Cited by 7
Overcoming Alcohol Addiction in Patients with Alcohol-Related Liver Disease
Im, G. Y. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00451-7 · Cited by 1
Molecular prognosis in liver cirrhosis
Divakar, S. K. A., & Hoshida, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801496-7.00021-6 · Cited by 1
Yoo, T. W., Lee, K., Yi, N., Hong, S. K., Lee, J., Kim, H., Lim, J., Seo, S., & Suh, K. (2020) · Clinical Transplantation · doi:10.1111/ctr.14011 · Cited by 1
Huang, H. Y. R., Awuah, W. A., Garg, T., Ng, J. C., Mehta, A., Ramamoorthy, K., Kalmanovich, J. B., & Hasan, M. M. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000743 · Cited by 2
“In addition to these genes, recent reports have also suggested that HSD17B13 is relevant to NAFLD through several genetic polymorphisms linked to lower risks of steatosis([15,20]).”
BackgroundPulmonary function, genetic predisposition, and the risk of cirrhosis: A prospective cohort study
Guo, R., Wang, L., Liu, T., Li, S., Liu, Y., Yang, H., Chen, L., Ji, C., & Xia, Y. (2024) · Preventive Medicine · doi:10.1016/j.ypmed.2024.108030 · Cited by 1
Self-citationNatural history of nonalcoholic fatty liver disease
Crocombe, D., & Tsochatzis, E. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00014-5 · Cited by 1
Demirtaş, C. Ö., Eren, F., Yilmaz, D., Özdogan, O. C., & Gündüz, F. (2024) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-5474 · Cited by 1
Unveiling the Multifaceted Role of CIDEB: From Apoptosis to Lipid Metabolism and Liver Health
Wutsdorff, L., Mougnekabol, J., Tang, P., Reutzel‐Selke, A., Sauer, I. M., & Haep, N. (2024) · Livers · doi:10.3390/livers4030030 · Cited by 1
miR‐6844/HSD17B13 Axis Contributes the Malignant Phenotype of Hepatocellular Carcinoma Cells
Liao, L., Yi, Q., Zhao, Z., Xu, M., Wu, T., Chen, S., & Liu, Y. (2025) · Cell Biology International · doi:10.1002/cbin.70025 · Cited by 1
Self-citationUsing metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis
Iruarrizaga‐Lejarreta, M., Arretxe, E., & Alonso, C. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1685379 · Cited by 1
“holic steatohepatitis [53,54], which also mitigates the risk of liver injury associated with the PNPLA3 I148M variant [53].”
BackgroundLiebe, R., & Keitel, V. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00647-2 · Cited by 1
miR-122-5p/KIF5B/AMPK/AKT regulatory network regulates the progression of NAFLD.
Zhang, J., & Huang, H. (2021) · American Journal of Translational Research · Cited by 3
RetractedGenes and lifestyle: Which of the two is more relevant in driving NAFLD progression?
Marchesini, G., & Taylor, R. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.08.011 · Cited by 1
Genetic predictors and pathophysiological features of non-alcoholic fat liver disease
Smirnova, O. V., Moskalenko, O. L., Каспаров, Э. В., & Каспарова, И. Э. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-15-78-87 · Cited by 1
Philips, C. A., Arab, J. P., Qi, X., Imai, N., & Augustine, P. (2022) · Springer eBooks · doi:10.1007/978-981-16-7672-7_6 · Cited by 1
Liebe, R., & Krawczyk, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_29 · Cited by 1
The Role of Senescence in NASH-Related HCC
Chrysavgis, L., Papadopoulos, G., & Chatzigeorgiou, A. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_87 · Cited by 2
Healthy lifestyle? or just the right genetic mutations
Butera, A., & Amelio, I. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2206351 · Cited by 1
“Often they are associated to attenuation of gene expression or protein activity [19,20].”
BackgroundEditorial: surviving your genes—the role of PNPLA 3 variation in end‐stage liver disease
Pirola, C. J., & Sookoian, S. C. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14901 · Cited by 1
Ma, Y., Brown, P. M., & Rotman, Y. (2019) · Hepatology · doi:10.1002/hep.31043 · Cited by 1
Non‐alcoholic Fatty Liver Disease
Rotman, Y., & Kapuria, D. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch52 · Cited by 2
Lammert, F. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch41 · Cited by 1
Therapeutic Approaches for Nonalcoholic Steatohepatitis ( NASH )
Glatthar, R., & Arch, R. H. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc274 · Cited by 1
Voilquin, L., Liu, T., Jung, Y., Taylor, N. P., Zhao, M., Charville, G. W., Nissen, S. B., Yki‐Järvinen, H., Altman, R. B., & Svensson, K. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.15.504026 · Cited by 1
Valenti, L. V. C., & Casirati, E. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17664 · Cited by 1
Mahmood, S., Morrice, N., Thompson, D., Milanizadeh, S., Wilson, S., Whitfield, P. D., Mcilroy, G. D., Rochford, J. J., & Mody, N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.27.582262 · Cited by 1
Hong, S. E., Mun, S. J., Lee, Y. J., Yoo, T., Suh, K., Kang, K. W., Son, M. J., Kim, W. S., & Choi, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.20.614203 · Cited by 1
Genetic and structural evidence links Ca 2+ dysregulation and ATP2B2 to neuropsychiatric illnessPreprint
Gerges, S., Straarup, N. C., El-Brolosy, M. A., Satterstrom, F. K., Kamitaki, N., Yuan, J., Ling, E., Gelze, C., Lin, R., Goldman, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.25.672202 · Cited by 3
Hoegeman, K. M., Wotring, J. W., Fursmidt, R. M., Gaetz, J., Khalil, E. M., Selinger, D. W., Kovalenko, I., Schultz, T. L., McCarty, S. M., O’Meara, M. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.12.693988 · Cited by 2
“66,78 This protective effect occurs despite these variants not typically altering simple steatosis levels, suggesting a role in downstream injury and fibrosis pathways.”
HSD17B11 maintains FSP1 localization on lipid droplets to support ferroptosis defensePreprint
Vazquez, V. F. M., Goodson, B. A., Kolaczkowski, O. M., Akter, H., Chen, L., Narang, N., Rajaiya, J., Rosas‐Lemus, M., & Pu, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.19.726342 · Cited by 1
“HSD17B11 is closely related to the LD protein HSD17B13, a liver-enriched factor genetically associated with protection from metabolic liver disease 20 .”
Commentary: 2017 clinical Epilepsia prize
Bien, C. G. (2018) · Epilepsia · doi:10.1111/epi.14430
Schaefer, B., Finkenstedt, A., Effenberger, M., Viveiros, A., Tilg, H., & Zoller, H. (2019) · Liver Transplantation · doi:10.1002/lt.25500
“86-fold higher risk for the development of hepatocellular cancer.(2) These data question the concept that incidental carriage without true A1ATD really exists.”
BackgroundGenes and NAFLD/NASH Progression
Sharkawy, R. E., George, J., & Eslam, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-37173-9_3 · Cited by 1
Highlights From the AASLD/EASL ALD Endpoints Conference 2019
Bertha, M., & Maddur, H. (2020) · Clinical Liver Disease · doi:10.1002/cld.927
Fatty Liver Disease: Metabolic, Genetic, or Both?
Zoller, H., Wagner, S., & Schaefer, B. (2020) · Hepatology Communications · doi:10.1002/hep4.1598
“This variant was primarily identified as providing protection from progressive fibrosis and cirrhosis in NAFLD and alcoholic liver disease rather than being a genetic determinant of liver fat.(8) This negative finding highlights the importance of disentangling the different components of the complex spectrum of fatty…”
BackgroundMechanisms of Fibrogenesis in NASH
Pastore, M., Gentilini, A., & Marra, F. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_6
Obesity and NAFLD: Same Problem?
Brodosi, L., Barbanti, F. A., Petroni, M. L., Marchignoli, F., & Marchesini, G. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_1
Agrawal, T., Gaggar, A., Subramanian, M. G., Kottilil, S., Choudhary, A., Rao, P. N., Shah, S., & Trehanpati, N. (2020) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2020.09.002
Karatas, E., & Bouchecareilh, M. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.09.003
Bayoumi, A. (2020) · The Sydney eScholarship Repository (The University of Sydney)
Personalised medicine for Non-Alcoholic Fatty Liver Disease
Taylor, A. (2021) · Discovery Research Portal (University of Dundee)
Weber, S. N., & Lammert, F. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_8
Lifestyle and Genetic Modifiers of Liver Disease Progression
Mandorfer, M., & Berzigotti, A. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_4
Nonalcoholic fatty liver disease
van Son, K. C., Holleboom, A. G., & Tushuizen, M. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822186-0.00024-9 · Cited by 2
Waller, K. M. J., Bowen, D. G., & Strasser, S. I. (2023) · Transplantation · doi:10.1097/tp.0000000000004474
Genetic Variants Determine Treatment Response in Autoimmune Hepatitis
Zandanell, S., Balcar, L., Semmler, G., Schirmer, A., Leitner, I., Rosenstatter, L., Niederseer, D., Sotlar, K., Schneider, A.-M., Straßer, M., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030540 · Cited by 1
Associations between genetic variants of HSD17B13 and fasting plasma glucose in Chinese children
Zhang, P.-P., Song, J., Li, L., Xu, M., Wang, H., & Wang, H.-J. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.027 · Cited by 1
Nonalcoholic Fatty Liver in the Pathogenesis of Diabetes
Nogueira, C. A. V., & Leite, N. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_16
Ткач, С. М., & Dogotar, V. B. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-2-34 · Cited by 1
“Це відкриття сприяло розробці ARO-HSD — терапевтичного препарату, що вибірково націлюється на мРНК HSD17B13 у гепатоцитах та зменшує експресію останнього як показано у клінічних дослідженнях фази 1 і 2а [24].”
InfluentialFischer, A. K., Semaan, A., Wulf, A., Vokuhl, C., Goltz, D., & Fischer, H.-P. (2023) · International Journal of Hepatology · doi:10.1155/2023/4313504 · Cited by 1
Hou, W., Watson, C., Cecconie, T., Bolaki, M. N., Brady Jennifer, J., Lu, Q., Gatto, G. J. J., & Day, T. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.18.562989
Etiopatogenia/fisiopatología de la enfermedad del hígado graso no alcohólica (NAFLD)
Quintero, M. A. R., & Pérez, J. N. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.esteatosis.art2 · Cited by 1
Nischalke, H. D., Schmalz, F., Fischer, J., Möller, C., Matz‐Soja, M., Krämer, B., Langhans, B., Nattermann, J., Berg, T., Strassburg, C. P., et al. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010002
Comorbid Conditions of Pediatric Obesity
Benavent, M. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-26727-7_6
Wattacheril, J. J., Kleinstein, S. E., Shea, P. R., Wilson, L., Subramanian, G. M., Myers, R. P., Lefkowitch, J. H., Behling, C. A., Xanthakos, S. A., & Goldstein, D. B. (2024) · medRxiv · doi:10.1101/2024.03.02.24303632 · Cited by 1
Mechanisms of Hepatic Steatosis
Mrdjen, M., Travers, J., & Nagy, L. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00079-6
Pirola, C. J., & Sookoian, S. C. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.006
Lean NAFLD: Prevalence, risk factors/pathogenesis, natural history, and treatment
Ito, T., & Takahashi, H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00001-7
林, 于. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.152520
Sun, H. J., Li, L., Xin, X. L., Yan, J., & Huang, T. (2025) · Discover Oncology · doi:10.1007/s12672-025-02019-y
“A loss-of-function variant in HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) was correlated with a decreased likelihood of developing chronic liver disease and a slowed progression from fatty liver (steatosis) to a more severe inflammation condition (steatohepatitis) [29].”
Pinheiro, M. M., Afonso, M. B., & Rodrigues, C. M. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-823524-9.00003-4
Alpha-1 Antitrypsin Deficiency
Cao, Z., & Huang, J. (2025) · Pracatical anatomic pathology · doi:10.1007/978-3-031-97506-6_5
HSD17B13 Couples Hepatocyte Lipid Metabolism to Stellate Cell Activation via TGFb-1 SignalingPreprint
Raymond, N., Lifshitz, L. M., Min, K., Lewis, C. A., Isaac, G., Yenilmez, B., & Czech, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.14.682191 · Cited by 1
Tang, S., Zhang, J., Mei, T.-T., Zhang, W. Y., Zheng, S.-J., & Yu, H.-B. (2021) · Figshare · doi:10.6084/m9.figshare.17304960
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Tavaglione, F., Ajmera, V. H., Díaz, L. A., Li, K., Madamba, E. V., Bettencourt, R., Richards, L., Hellerstein, M. K., & Loomba, R. S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101733
Lunnerdal, S., Wågberg, F., Dahl, G., Ahnmark, A., Hansson, P., Sampers, E. N. R., Madeyski-Bengtson, K., Lee, W., Löfgren, L., Zarrouki, B., et al. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00697
Macrophage-specific N-terminal truncation of Plin2 limits the size of lipid droplets
Tian, Y., Huang, X., & Wei, Y. (2026) · Biochemical Journal · doi:10.1042/bcj20253345
“Metabolic disorders such as obesity, fatty liver disease, and atherosclerosis are closely associated with intracellular LD load capacity [15–18].”
De Novo and Recurrent Metabolic Dysfunction Associated Steatotic Liver Disease
Parsa, L., & Satapathy, S. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-2624-6_37
MASLD – Krankheitslast, Herausforderungen und neue Therapeutika
Roeb, E. (2026) · Schweizer Gastroenterologie · doi:10.1007/s43472-026-00189-w
Min, J., Seneshaw, M., Mirshahi, F., Min, H., & Sanyal, A. J. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101793
“4 Following enzymatic digestion, semi-quantitative RT-PCR was performed using primers flanking exon 2 to simultaneously detect the isoform, while ACTB (155 bp) served as the internal normalization control.”
InfluentialArriaga-González, F. G., Castañeda-Córdova, F. D. J., Díaz‐Muñoz, M., Hoare, M., Adams, D. J., Robles‐Espinoza, C. D., & Molina‐Aguilar, C. (2026) · BMC Medical Genomics · doi:10.1186/s12920-026-02332-7 · Cited by 2
“The protective effects of alleles in MTARC1 and HSD17B13 are also amplified directly by body adiposity, where patients with elevated BMI presented a lower degree of hepatic steatosis than leaner patients [68, 80].”
Precision medicine in steatotic liver disease
Prasitsumrit, V., & Chen, V. L. (2026) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001165
Patel, V., Navale, A. M., & Singh, P. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02306-x
Steatotic Liver Disease: Does Existing Non-Invasive Markers Fit the Updated Nomenclature?
Kothari, K. T., Jothimani, D. K., & Rela, M. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00727-9
Maintenance des télomères dans la carcinogenèse hépatique : fonction et transfert vers la clinique
Ningarhari, M. (2022) · theses.fr (ABES) · doi:10.70675/f313264az1d77z4572z8a2dz6fc821d54a58
Identification des nouveaux déterminants génétiques prédisposant aux carcinomes hépatocellulaires
Yang, J. (2019) · theses.fr (ABES) · doi:10.70675/6f60acd0z1345z4e7aza75bzb9b14c6ced0c
Lee, S. Y., & Shin, H. D. (2026) · Journal of Viral Hepatitis · doi:10.1111/jvh.70175
“The gene produces a protein localized to hepatic lipid droplets, and its loss- of-function variants are known to reduce the risk of hepatic inflammation [24, 25].”
Impact de l'obésité sur la toxicologie des contaminants alimentaires : l'exemple de la Fumonisine B1
Dopavogui, L. (2022) · theses.fr (ABES) · doi:10.70675/8fcfcad7z134cz4df2zade9z155636aa8994 · Cited by 1
Circulating biomarkers of response to systemic treatments in advanced hepatocellular carcinoma
Campani, C. (2023) · theses.fr (ABES) · doi:10.70675/3ec25263z4942z4eb1zbc98z0ec33fa57a18
Xu, X. G., Liu, Y., Yang, Z., Wu, Z., Guo, W., Yang, M., Xia, J., Wu, C., Li, Z., & Cheng, G. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109843
Self-citationBoppana, S. H., Luke, N., Karuchola, S., Udaikumar, J., & Mintz, C. D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040455
“Given the real-world demonstration of safe and effective mRNA vaccines during the COVID-19 pandemic [71,72], it is reasonable to expect broader application of mRNA-based therapeutics across medicine, including hepatology.”
Kang, S. W., Kim, S. K., Ban, J. Y., & Park, M. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093920 · Cited by 1
Self-citationMapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology
Pirola, C. J., & Sookoian, S. C. (2026) · Med · doi:10.1016/j.medj.2026.101131 · Cited by 2
Aina, K. O. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102616
“This effect is associated with decreased retinol dehydrogenase activity, altered retinol metabolism, and attenuation of fibrotic progression, and can partially offset the deleterious effects of the PNPLA3 I148 M allele [90].”
Meat Intake, Genetic Predispositions, and the Risk of Steatotic Liver Disease in a Cohort Study
Xu, Y.-W., Liang, S., Li, M., 常瑜, Chen, J., Qin, X., Cao, H., Zhang, Z., & Yang, W. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101600
Gobeil, É., Bourgault, J., Enault, M., Côté, V., Mitchell, P. L., Ruel, L., Girard, A. S., Vohl, M., & Arsenault, B. J. (2026) · medRxiv · doi:10.64898/2026.06.04.26354903
Hepatogenomics of MAFLD in Asian Population: Genetic Polymorphisms and Pathway-Based Insights
Justyn, M., Sutanto, C., Barliana, M. I., Heryaman, H., Meiliana, A., & Puspitasari, I. M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s603042
Possible correlations between infertility and adverse metabolic profile: a case-control study
Aquino, C. I., Vercellino, N., Elisabetta, F., Ferrante, D., Rigamonti, C., Rosalba, M., Pirisi, M., Valentino, R., Bellan, M., & Daniela, S. (2026) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2026.115250
Genetic and epigenetic landscape of type 2 diabetes mellitus
Patil, P. C., Surve, S., Kaleem, M., Kayali, A., & Bachhav, R. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33590-7.00012-5
Wang, Q., Zhang, B., Wang, Y., Xu, X., Zuo, K., Luo, J., Fan, H., Li, Z., Pan, H., & Jiang, S. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09111
Self-citationPrime editing enables isogenic modeling of PNPLA3-I148M-associated lipotoxicity in hepatocytes
Noguchi, H., Uchida, T., Wakita, N., Takenaga, M., Sakuma, T., Murakami, S., Inomata, M., Ono, A., Hagiwara, H., Hirashita, Y., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102993
“21 Consistent with this protective background, we observed relatively attenuated stress responses to PA treatment in Huh7 cells compared to HepG2 cells (Figure S3).”
Loss of Ambp ameliorates steatosis progression by activating PPARα signaling in zebrafish
Zhou, L., Cheng, J., Wu, M., Tu, M., Zheng, Y., Ning, G., Li, J., Zhang, L., & Zhang, J. (2026) · FEBS Journal · doi:10.1111/febs.70641
Jiang, W., Yang, Z., Cui, Y., Huang, N., Dong, L., Sun, T., & Zhang, B. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1902349
“Tier 3 (investigational) consists of genetic testing for PNPLA3/TM6SF2, microbiome profiling, and targeted supplementation (100, 101, 104, 111), which require randomized controlled trial validation (106) before clinical implementation.”
Wu, C., Sang, J., Xu, Q., Zhan, Y., Yuan, S.-J., Ge, Y.-Y., Yu, X.-J., Zheng, X., Wang, X.-F., He, X.-M., et al. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01987-w
Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology
Crespo, J., Alonso‐Peña, M., Jiménez-González, C., Cayon, L., & Iruzubieta, P. (2026) · Pharmaceuticals · doi:10.3390/ph19081145
“…earliest PRS models primarily integrated PNPLA3, TM6SF2, MBOAT7, and GCKR, demonstrating moderate ability to predict advanced fibrosis and HCC. Subsequent incorporation of additional loci identified through multi-ancestry GWAS progressively improved the biological resolution of these models…”
Influential
Metadata
- Authors
- Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., Stepanchick, A. N., Still, M. D., McCarthy, S., O’Dushlaine, C., Packer, J. S., Balasubramanian, S., Gosalia, N., Esopi, D., Kim, S. Y., Mukherjee, S., Lopez, A. E., Fuller, E. D., Penn, J., Chu, X., Luo, J. Z., Mirshahi, U. L., Carey, D. J., Still, C. D., Feldman, M. D., Small, A., Damrauer, S. M., Rader, D. J., Zambrowicz, B., Olson, W., Murphy, A. J., Borecki, I. B., Shuldiner, A. R., Reid, J. G., Overton, J. D., Yancopoulos, G. D., Hobbs, H. H., Cohen, J. C., Gottesman, O., Teslovich, T. M., Baras, A., Mirshahi, T., Gromada, J., & Dewey, F. E.
- Affiliations
- From the Regeneron Genetics Center (N.S.A.-H., A.H.L., C.S., S. McCarthy, C.O., J.S.P., S.B., N.G., S. Mukherjee, A.E.L., E.D.F., J.P., I.B.B., A.R.S., J.G.R., J.D.O., O.G., T.M.T., A.B., F.E.D.) and Regeneron Pharmaceuticals (X. Cheng, Y.X., P.S., Y.L., D.E., S.Y.K., B.Z., W.O., A.J.M., G.D.Y., J.G.), Tarrytown, NY; the University of Texas Southwestern Medical Center at Dallas, Dallas (J.K., S.S., H.H.H., J.C.C.); and Geisinger Health System, Danville (G.C.W., A.N.S., M.D.S., X. Chu, J.Z.L., U.L.M....
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- ORCID
- Cheng, Xiping
- Li, Alexander H.
- Xin, Yurong
- Schurmann, Claudia
- Liu, Yashu
- Kozlitina, Julia
- Stender, Stefan
- Wood, G. Craig
- Still, Matthew D.
- O’Dushlaine, Colm
- Packer, Jonathan S.
- Balasubramanian, Suganthi
- Gosalia, Nehal
- Esopi, David
- Kim, Sun Y.
- Mukherjee, Semanti
- Lopez, Alexander E.
- Chu, Xin
- Luo, Jonathan Z.
- Mirshahi, Uyenlinh L.
- Carey, David J.
- Still, Christopher D.
- Feldman, Michael D.
- Small, Aeron
- Damrauer, Scott M.
- Rader, Daniel J.
- Zambrowicz, Brian
- Olson, William
- Murphy, Andrew J.
- Borecki, Ingrid B.
- Shuldiner, Alan R.
- Reid, Jeffrey G.
- Overton, John D.
- Hobbs, Helen H.
- Cohen, Jonathan C.
- Baras, Aris
- Mirshahi, Tooraj
- Gromada, Jesper
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-22
- Volume
- 378
- Issue
- 12
- Pages
- 1096-1106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6668033
- OpenAlex
- W2793543636
- Cited by
- 827
- References
- 32
- Citations by year
- 2026: 101 · 2025: 104 · 2024: 82 · 2023: 104 · 2022: 100 · 2021: 109 · 2020: 127 · 2019: 67 · 2018: 32
- FWCI
- 48.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Perelman School of Medicine, University of Pennsylvania
- Smilow Foundation
- National Institutes of Health (P30DK072488, UL1TR001105)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- HSD17B13, chronic liver disease, loss-of-function mutations, alcoholic liver disease, non-alcoholic liver disease, alcoholic cirrhosis, non-alcoholic cirrhosis, nonalcoholic steatohepatitis, steatosis, alanine aminotransferase, aspartate aminotransferase, PNPLA3, liver histopathology
- MeSH terms
- Exome Sequencing, Loss of Function Mutation, Alanine Transaminase, Aspartate Aminotransferases, Chronic Disease, Fatty Liver, Female, Genotype, Humans, Liver, Liver Diseases, Male, Genetic Variation, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Linear Models, Sequence Analysis, RNA, Disease Progression, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.